Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.

Pokorna Z, Jirkovsky E, Hlavackova M, Jansova H, Jirkovska A, Lencova-Popelova O, Brazdova P, Kubes J, Sotakova-Kasparova D, Mazurova Y, Adamcova M, Vostatkova L, Holzerova K, Kolar F, Simunek T, Sterba M.

Clin Sci (Lond). 2019 Aug 27;133(16):1827-1844. doi: 10.1042/CS20190139. Print 2019 Aug 30.

PMID:
31409729
2.

Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials.

Reimerová P, Stariat J, Bavlovič Piskáčková H, Jansová H, Roh J, Kalinowski DS, Macháček M, Šimůnek T, Richardson DR, Štěrbová-Kovaříková P.

Anal Bioanal Chem. 2019 Apr;411(11):2383-2394. doi: 10.1007/s00216-019-01681-w. Epub 2019 Mar 1.

PMID:
30820631
3.

2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress.

Jansová H, Kubeš J, Reimerová P, Štěrbová-Kovaříková P, Roh J, Šimůnek T.

Chem Res Toxicol. 2018 Nov 19;31(11):1151-1163. doi: 10.1021/acs.chemrestox.8b00165. Epub 2018 Nov 5.

PMID:
30395451
4.

Cardiac resynchronization therapy guided by cardiac magnetic resonance imaging: A prospective, single-centre randomized study (CMR-CRT).

Kočková R, Sedláček K, Wichterle D, Šikula V, Tintěra J, Jansová H, Pravečková A, Langová R, Krýže L, El-Husseini W, Segeťová M, Kautzner J.

Int J Cardiol. 2018 Nov 1;270:325-330. doi: 10.1016/j.ijcard.2018.06.009. Epub 2018 Jun 6.

PMID:
29908832
5.

Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.

Bures J, Jirkovska A, Sestak V, Jansova H, Karabanovich G, Roh J, Sterba M, Simunek T, Kovarikova P.

Toxicology. 2017 Dec 1;392:1-10. doi: 10.1016/j.tox.2017.09.012. Epub 2017 Sep 21.

PMID:
28941780
6.

Cardioprotective Potential of Iron Chelators and Prochelators.

Jansová H, Šimůnek T.

Curr Med Chem. 2019;26(2):288-301. doi: 10.2174/0929867324666170920155439. Review.

PMID:
28933303
7.

Ultrasound-guided versus conventional femoral venipuncture for catheter ablation of atrial fibrillation: a multicentre randomized efficacy and safety trial (ULTRA-FAST trial).

Yamagata K, Wichterle D, Roubícek T, Jarkovský P, Sato Y, Kogure T, Peichl P, Konecný P, Jansová H, Kucera P, Aldhoon B, Cihák R, Sugimura Y, Kautzner J.

Europace. 2018 Jul 1;20(7):1107-1114. doi: 10.1093/europace/eux175.

PMID:
28575490
8.

Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?

Lenčová-Popelová O, Jansová H, Jirkovský E, Bureš J, Jirkovská-Vávrová A, Mazurová Y, Reimerová P, Vostatková L, Adamcová M, Hroch M, Pokorná Z, Kovaříková P, Šimůnek T, Štěrba M.

Toxicology. 2016 Nov 30;372:52-63. doi: 10.1016/j.tox.2016.11.002. Epub 2016 Nov 2.

PMID:
27816693
9.

Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury.

Hašková P, Jansová H, Bureš J, Macháček M, Jirkovská A, Franz KJ, Kovaříková P, Šimůnek T.

Toxicology. 2016 Sep 14;371:17-28. doi: 10.1016/j.tox.2016.10.004. Epub 2016 Oct 12.

10.

Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.

Jansová H, Bureš J, Macháček M, Hašková P, Jirkovská A, Roh J, Wang Q, Franz KJ, Kovaříková P, Šimůnek T.

Toxicology. 2016 Mar 28;350-352:15-24. doi: 10.1016/j.tox.2016.03.004. Epub 2016 Apr 1.

11.

Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.

Lenčová-Popelová O, Jirkovský E, Jansová H, Jirkovská-Vávrová A, Vostatková-Tichotová L, Mazurová Y, Adamcová M, Chládek J, Hroch M, Pokorná Z, Geršl V, Šimůnek T, Štěrba M.

J Mol Cell Cardiol. 2016 Feb;91:92-103. doi: 10.1016/j.yjmcc.2015.12.021. Epub 2015 Dec 23.

PMID:
26724189
12.

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents.

Sestak V, Stariat J, Cermanova J, Potuckova E, Chladek J, Roh J, Bures J, Jansova H, Prusa P, Sterba M, Micuda S, Simunek T, Kalinowski DS, Richardson DR, Kovarikova P.

Oncotarget. 2015 Dec 15;6(40):42411-28. doi: 10.18632/oncotarget.6389.

13.

In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites.

Potůčková E, Roh J, Macháček M, Sahni S, Stariat J, Šesták V, Jansová H, Hašková P, Jirkovská A, Vávrová K, Kovaříková P, Kalinowski DS, Richardson DR, Šimůnek T.

PLoS One. 2015 Oct 13;10(10):e0139929. doi: 10.1371/journal.pone.0139929. eCollection 2015.

14.

LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH).

Bureš J, Jansová H, Stariat J, Filipský T, Mladěnka P, Šimůnek T, Kučera R, Klimeš J, Wang Q, Franz KJ, Kovaříková P.

J Pharm Biomed Anal. 2015 Feb;105:55-63. doi: 10.1016/j.jpba.2014.11.044. Epub 2014 Dec 3.

15.

Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.

Potůčková E, Hrušková K, Bureš J, Kovaříková P, Špirková IA, Pravdíková K, Kolbabová L, Hergeselová T, Hašková P, Jansová H, Macháček M, Jirkovská A, Richardson V, Lane DJ, Kalinowski DS, Richardson DR, Vávrová K, Šimůnek T.

PLoS One. 2014 Nov 13;9(11):e112059. doi: 10.1371/journal.pone.0112059. eCollection 2014.

16.

Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.

Jansová H, Macháček M, Wang Q, Hašková P, Jirkovská A, Potůčková E, Kielar F, Franz KJ, Simůnek T.

Free Radic Biol Med. 2014 Sep;74:210-21. doi: 10.1016/j.freeradbiomed.2014.06.019. Epub 2014 Jun 30.

17.

High-density epicardial activation mapping to optimize the site for video-thoracoscopic left ventricular lead implant.

Polasek R, Skalsky I, Wichterle D, Martinca T, Hanuliakova J, Roubicek T, Bahnik J, Jansova H, Pirk J, Kautzner J.

J Cardiovasc Electrophysiol. 2014 Aug;25(8):882-888. doi: 10.1111/jce.12430. Epub 2014 May 12.

18.

Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.

Potuckova E, Jansova H, Machacek M, Vavrova A, Haskova P, Tichotova L, Richardson V, Kalinowski DS, Richardson DR, Simunek T.

PLoS One. 2014 Feb 20;9(2):e88754. doi: 10.1371/journal.pone.0088754. eCollection 2014.

19.

Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.

Vavrova A, Jansova H, Mackova E, Machacek M, Haskova P, Tichotova L, Sterba M, Simunek T.

PLoS One. 2013 Oct 7;8(10):e76676. doi: 10.1371/journal.pone.0076676. eCollection 2013.

20.

Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.

Macková E, Hrušková K, Bendová P, Vávrová A, Jansová H, Hašková P, Kovaříková P, Vávrová K, Simůnek T.

Chem Biol Interact. 2012 May 30;197(2-3):69-79. doi: 10.1016/j.cbi.2012.03.010. Epub 2012 Apr 11.

PMID:
22521999

Supplemental Content

Loading ...
Support Center